| __timestamp | Mesoblast Limited | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 55305000 | 1271353000 |
| Thursday, January 1, 2015 | 77593000 | 1620577000 |
| Friday, January 1, 2016 | 50013000 | 2052295000 |
| Sunday, January 1, 2017 | 58914000 | 2075142000 |
| Monday, January 1, 2018 | 65927000 | 2186100000 |
| Tuesday, January 1, 2019 | 59815000 | 3036600000 |
| Wednesday, January 1, 2020 | 56188000 | 2735000000 |
| Friday, January 1, 2021 | 53012000 | 2908100000 |
| Saturday, January 1, 2022 | 32815000 | 3592500000 |
| Sunday, January 1, 2023 | 27189000 | 4439000000 |
| Monday, January 1, 2024 | 25353000 | 5132000000 |
Unleashing the power of data
In the competitive world of biotechnology, innovation is the lifeblood of success. Regeneron Pharmaceuticals, Inc. and Mesoblast Limited are two prominent players, each with a unique approach to research and development (R&D) investment. Over the past decade, Regeneron has consistently outpaced Mesoblast in R&D spending, with an average annual investment nearly 50 times greater. In 2023, Regeneron's R&D expenses soared to an impressive $4.4 billion, marking a 250% increase since 2014. In contrast, Mesoblast's investment peaked in 2015 and has since declined by over 65%, reaching approximately $27 million in 2023. This stark contrast highlights Regeneron's commitment to innovation, while Mesoblast faces challenges in maintaining its R&D momentum. As the biotech landscape evolves, these investment strategies will undoubtedly shape the future of medical breakthroughs.
R&D Insights: How Merck & Co., Inc. and Regeneron Pharmaceuticals, Inc. Allocate Funds
Amgen Inc. vs Mesoblast Limited: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Alnylam Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Summit Therapeutics Inc.
Regeneron Pharmaceuticals, Inc. or TG Therapeutics, Inc.: Who Invests More in Innovation?
R&D Spending Showdown: Regeneron Pharmaceuticals, Inc. vs Viking Therapeutics, Inc.
Comparing Innovation Spending: Regeneron Pharmaceuticals, Inc. and ImmunityBio, Inc.
Regeneron Pharmaceuticals, Inc. vs Mesoblast Limited: Efficiency in Cost of Revenue Explored
Regeneron Pharmaceuticals, Inc. or Arrowhead Pharmaceuticals, Inc.: Who Invests More in Innovation?
R&D Insights: How Regeneron Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. Allocate Funds
R&D Insights: How CymaBay Therapeutics, Inc. and Mesoblast Limited Allocate Funds
Supernus Pharmaceuticals, Inc. vs Mesoblast Limited: Strategic Focus on R&D Spending